Replies to post #190041 on Biotech Values

[DewDiligence]

BMY—CheckMate-025 Opdivo trial in second-line RCC stopped early for OS superiority vs Afinitor control arm:

http://finance.yahoo.com/news/checkmate-025-pivotal-phase-iii-120000343.html

Details (including the HR and p-value) will be presented at a medical conference.

This is Opdivo’s sixth or seventh trial stopped early for efficacy (I’ve lost count), but the first one stopped early for efficacy in OS specifically.

[DewDiligence]

BMY—PDUFA date for Opdivo in 2nd-line non-squamous NSCLC is 1/2/16 (with BTD and priority review):

http://finance.yahoo.com/news/u-food-drug-administration-accepts-120000453.html